Add to ORKGWe have evaluated drug retention rate and predictive factors of drug survival for interleukin-1 inhibitors in systemic juvenile idiopathic arthritis. Our findings suggest an excellent overall drug retention rate for both anakinra and canakinumab that might be further augmented by paying attention to adverse events and employing these agents as first-line biologics in an early disease phase
The pharmacokinetics and pharmacodynamic (PD) properties of a monoclonal antibody, canakinumab, in p...
Objective: The objective of this study was to use real-world data to evaluate the effectiveness and ...
Interleukin-1 is pivotal in the pathogenesis of systemic juvenile idiopathic arthritis (JIA). We ass...
We have evaluated anakinra drug retention rate and predictive factors of drug survival in a cohort o...
Background and Objectives: Few studies have reported the drug retention rate (DRR) of biologic drugs...
Background and Objectives: Few studies have reported the drug retention rate (DRR) of biologic drugs...
Background and Objective: Only a few studies have reported long-term efficacy of interleukin (IL)-1 ...
Background and objective: Only a few studies have reported long-term efficacy of interleukin (IL)-1 ...
Joachim Peitz, Gerd Horneff Pediatric Rheumatology Centre, Department of General Pediatrics and Neon...
To investigate survival of IL-1 inhibitors in monogenic autoinflammatory disorders (mAID) through dr...
Objective: To evaluate in real-life the effectiveness and safety of canakinumab in Italian patients ...
Introduction: Systemic juvenile idiopathic arthritis (sJIA) accounts for 10-20% of all patients with...
The pharmacokinetics and pharmacodynamic (PD) properties of a monoclonal antibody, canakinumab, in p...
Objective: The objective of this study was to use real-world data to evaluate the effectiveness and ...
Interleukin-1 is pivotal in the pathogenesis of systemic juvenile idiopathic arthritis (JIA). We ass...
We have evaluated anakinra drug retention rate and predictive factors of drug survival in a cohort o...
Background and Objectives: Few studies have reported the drug retention rate (DRR) of biologic drugs...
Background and Objectives: Few studies have reported the drug retention rate (DRR) of biologic drugs...
Background and Objective: Only a few studies have reported long-term efficacy of interleukin (IL)-1 ...
Background and objective: Only a few studies have reported long-term efficacy of interleukin (IL)-1 ...
Joachim Peitz, Gerd Horneff Pediatric Rheumatology Centre, Department of General Pediatrics and Neon...
To investigate survival of IL-1 inhibitors in monogenic autoinflammatory disorders (mAID) through dr...
Objective: To evaluate in real-life the effectiveness and safety of canakinumab in Italian patients ...
Introduction: Systemic juvenile idiopathic arthritis (sJIA) accounts for 10-20% of all patients with...
The pharmacokinetics and pharmacodynamic (PD) properties of a monoclonal antibody, canakinumab, in p...
Objective: The objective of this study was to use real-world data to evaluate the effectiveness and ...
Interleukin-1 is pivotal in the pathogenesis of systemic juvenile idiopathic arthritis (JIA). We ass...